Close Menu

Anita Hauser, Pius Baschera

Dec 05, 2016

The Roche board of directors has proposed that Anita Hauser be elected to the board at its annual general meeting, scheduled for March 14, 2017. If elected, Hauser will replace Pius Baschera, a member of the Roche board since 2007, who will not stand for re-election. Hauser is managing director at Magenta Management. Prior to joining Magenta, she was country manager and director at EF Education First. She is also vice chairwoman of the board of directors of Bucher Industries and a member of the boards of Glatz and Amag Automobil und Motoren.

More Like This

May 28, 2020

Gradientech: Gisela Sitbon, Rolf Ehrnström, Simon Turner

Gradientech has added three new board members: Gisela Sitbon, Rolf Ehrnström, and Simon Turner. Sitbon boasts more than 25 years of senior level life science experience and will be the new chair of the board at the Uppsala, Sweden-based developer of rapid phenotypic antibiotic suceptibility testing. Ehrnström, meanwhile, has experience in research and development at companies such as Amersham Pharmacia Biotech, Dako, and Gyros, while Turner is an investment analyst.

May 28, 2020

First Light Diagnostics: Andrew Wilsack

First Light Diagnostics has appointed Andrew Wilsack its CFO. He has more than 25 years of experience in the life science industry, including most recently as a financial consultant at Danforth Advisors. Previously, he was vice president of FPA at Masimo and CFO at Argose. 

May 28, 2020

Myriad Genetics: John Henderson, Daniel Spiegelman

Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point S. Louise Phanstiel was elected to serve as chair. The company has also elected to its board of directors Daniel Spiegelman, who was most recently executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.

May 27, 2020

AXIM Biotechnologies: Sergei Svarovsky

AXIM Biotechnologies has appointed Sergei Svarovsky as the CSO of subsidiary Sapphire Biotech. Svarovsky previously served as a research fellow at the National Institute of Health's National Cancer Institute. AXIM noted that Svarovsky has experience with cancer drug design medical diagnostics develompent, including developing a wide range of biological assays for existing and novel platforms for many well-known biotech firms. 

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry as its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

May 26, 2020

Proteomedix: Maurizo Ballerini, Helene Peyro Saint-Paul

Swiss cancer diagnostics company Proteomedix has appointed Maurizo Ballerini as vice president of market development for Europe, the Middle East, and Africa, and Helene Peyro Saint-Paul as medical advisor. Both appointments are effective June 1. Ballerini has held medical, commercial, and management positions with MDxHealth, GenProbe, now part of Hologic, Stryker, Randox Laboratories, and Abbott Laboratories. Peyro Saint-Paul has held corporate leadership positions at Serono, Ipsogen, and Qiagen. 

May 26, 2020

Freenome: Bill Quirk, Gary Reedy

Freenome has hired Bill Quirk as its chief financial officer. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler. He received a BA in business administration from Saint Norbert College, an MBA from the University of Minnesota’s Carlson School of Management, and holds the CFA designation.

The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He boasts a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson. Reedy is a graduate of Emory & Henry College and holds an honorary Doctor of Humane Letters degree from Arcadia University.

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18. 

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America. 

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

May 12, 2020

Alveo Technologies: Bharat Tewarie

Alveo Technologies has appointed Bharat Tewarie to its board of directors. Tewarie recently founded Boston BioPharma Consultants and was formerly executive vice president and chief marketing officer at biopharma firm UCB. He currently is on the board of Ahara Biosciences and Duluth Medical Technologies. Alameda, California-based Alveo is developing an at-home diagnostic platform called be.well that leverages nucleic acid amplification for the molecular detection of infectious diseases.

May 11, 2020

Roche: Fritz Gerber

Roche announced that former Group CEO and Chairman of the Board Fritz Gerber died at 92. Gerber served as group CEO from 1978 to 1998 and decentralized the company's structures. Under his leadership, Roche acquired a majority stake in Genentech, took over Boehringer Mannheim, and acquired PCR technology. After retiring as chairman in 2001, he remained an honorary chairman throughout the rest of his life. 

Gerber was also on the board of IBM and created the Fritz Gerber Foundation for Gifted Young People.

May 06, 2020

Centogene: Angelos Baxevanis

Angelos Baxevanis has joined Centogene as senior vice president of communication and marketing. He joins the company from AAB Consulting, where he worked with Sobi Pharmaceuticals on enhancing commercial capabilities for rare disease. Prior to that, he led marketing communication and excellence at Smith & Nephew, and before that, he held several positions at Astra Zeneca. Baxevanis has an MBA from the Alba Graduate Business School and a master's degree in chemical engineering from the University of Patras in Greece.

May 06, 2020

OraSure Technologies: Lisa Nibauer

OraSure Technologies has appointed Lisa Nibauer as executive vice president and business unit leader for infectious disease. She will replace Tony Zezzo, who has announced that he will retire from the company. Zezzo's official retirement date will be mutually determined, and he will maintain his current role in OraSure's COVID-19 activities while he coordinates the transition with Nibauer, who will join the company on May 11. Nibauer most recently served as vice president and general manager of global medication delivery solutions at Becton Dickinson.

May 06, 2020

First Light Diagnostics: Joanne Spadoro

First Light Diagnostics announced that Joanne Spadoro is the company's COO. Last September she joined the company as VP of R&D and regulatory affairs. Previously, Spadoro was senior VP of product development and operations at Roche Molecular Systems, leading the teams that launched PCR-based products globally for infectious disease diagnostics, viral load monitoring, and blood screening applications. 

She also served as CSO and worldwide VP of operations at Immucor, developing the company's molecular immunohematology test for the detection of extended blood antigens. Spadoro was also previously the COO at T2 Biosystems.